Immune booster shows promise in fighting dangerous fungal infection
NCT ID NCT04979052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether adding interferon-gamma to standard antifungal treatment helps clear Candida from the blood faster. 65 adults with candidemia received the drug or standard care alone. The study is completed, and results will show if this combination is safe and speeds up recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Interferon gamma-1b (Immukin)
What this could lead to
If it works, this could offer a way to help the immune system fight Candida bloodstream infections more quickly, reducing hospital stays.
What could go wrong
This is an early Phase 2 trial with only 65 participants, so results may not apply to everyone. Adding an immune booster may also cause side effects like fever or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1005, Switzerland
-
Duke University
Durham, North Carolina, 27708, United States
-
Hellenic Institute for the Study of Sepsis (HISS)
Athens, 11528, Greece
-
Klinikum Der Johann Wolfgang Von Goethe Universitaet
Frankfurt am Main, 60590, Germany
-
Radboudumc
Nijmegen, Gelderland, 6525 GA, Netherlands
-
Universitatea de Medicina si Farmacie luliu Hatieganu
Cluj-Napoca, 400348, Romania